secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbCellera Biologics Inc. (ABCL)
CIK:        0001703057
Form:       8-K
Filed at:   2021-11-04T23:59:59+00:00
Accession:  0001564590-21-054498
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbCellera announces U.S. government purchase of 614,000 doses of bamlanivimab/etesevimab for $1.29B
--------------------------------------------------------------------------------

- Lilly will supply 614,000 additional doses no later than January 31, 2022; minimum 400,000 by December 31, 2021.
- Total agreement value is $1.29 billion for bamlanivimab with etesevimab, discovered by AbCellera.
- The antibody therapy has treated over 535,000 patients in the U.S., potentially preventing 25,000 hospitalizations.
- AbCellera receives royalties from Lilly on sales of bamlanivimab and etesevimab.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1703057/000156459021054498/0001564590-21-054498-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1703057/000156459021054498/abcl-8k_20211102.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-054498

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer